A Phase III Randomized Study of Zolendronate Bisphosphonate Therapy for the Prevention of Bone Loss in Men With Prostate Cancer Receiving Long-Term Androgen Deprivation.

Trial Profile

A Phase III Randomized Study of Zolendronate Bisphosphonate Therapy for the Prevention of Bone Loss in Men With Prostate Cancer Receiving Long-Term Androgen Deprivation.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Calcium gluconate; Colecalciferol; Zoledronic acid
  • Indications Male osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Mar 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2020.
    • 15 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top